Avacta Group plc
AGM Statement
At today's AGM of Avacta Group plc ("Avacta" or the "Company"), which provides
biophysics based analysis technology and services, Prof. Alastair Smith, Chief
Executive, made the following statement:
"We have enjoyed an excellent beginning to the current financial year in terms
of building our revenue-generating pharmaceutical services business, whilst
pushing forward strongly with our principal product development - a technology
to help reduce the cost and risks associated with biopharmaceutical drug
development which is expected to launch in late 2008.
"Additional technology products are also being prototyped and we are in
discussions with several potential commercial partners to deliver clear routes
to market for these additional products aimed at chemical and biological
detection and point-of-care diagnostics and we hope to announce further news in
the coming months.
"In conclusion, we have exceeded the initial targets we set ourselves when
Avacta Group floated in autumn 2006 and are on schedule to deliver on our plans
laid in April this year. We look forward to keeping investors informed via
regular news flow during the coming months."
14 December 2007
Enquiries:
Avacta Group plc Tel: 0870 835 4367
Alastair Smith, Chief Executive
Nexus Financial Ltd Tel: 020 7451 7050
Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk
WH Ireland Limited Tel: 0161 832 2174
David Youngman/Robin Gwyn
BankOra Limited - Nominated Broker Tel: 020 7562 4713
Henry Turcan/Michael Brennan
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.